We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Breathalyzer Monitors Blood Glucose in Diabetics

By LabMedica International staff writers
Posted on 26 Nov 2013
A novel noninvasive breathalyzer device has been created that can monitor blood glucose levels in diabetics by detecting acetone levels. More...


Current technology to measure blood glucose includes the use of a portable testing meter that can measure sugar levels in the body from a small drop of blood, but it is invasive, can often cause discomfort for the patient, and can lead to low compliance with poor health consequences.

Scientists at the Western New England University (Springfield, MA, USA) produced a hand-held breathalyzer that uses nanometer-thick films that are made up of two polymers. These polymers are able to react with acetone. Acetone is one of the ketones, which are acids that remain in the body when the body burns its own fat. Ketones build up when there is not enough insulin to help fuel the body's cells, meaning they are more common in people with diabetes.

In the breathalyzer device, the acetone adheres to the polymers and alters the physical chemistry of the film. The film then discloses the amount of acetone detected, which in turn reveals glucose levels in the blood. At present, the breathalyzer is similar in size to a book; however, an engineer at Western New England University is helping to make the device similar in size to breathalyzers that are used to detect blood alcohol content levels.

Ronny Priefer, PhD, the designer of the device said, “Breathalyzers are a growing field of study because of their potential to have a significant positive impact on patients' quality of life and compliance with diabetes monitoring. What makes our technology different is that it only accounts for acetone and doesn't react with other components in the breath.”

Prof. Preifer added that common shortfalls with other breathalyzer technologies have included inconsistent results due to natural humidity in the breath, high temperature requirements, and lack of differentiation. The study was presented at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition held November 10-14, 2013, in San Antonio (TX, USA).

Related Links:

Western New England University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Thyroid Test
Anti-Thyroid EIA Test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.